Antibodies

Medical researcher
#Antibodies #App note #Biosimilars #Kinetics #Screening

App Note: Kinetic screening for rapid biosimilar testing

A new App Note is now available for download entitled ‘Fcγ Receptor and Antigen Kinetic Screening for Rapid Biosimilar Downstream Processing Assessment’. Demonstrating similarity of biomolecules such as antibodies throughout upstream and downstream production processes is crucial. A rapid testing method is demonstrated using a Humira biosimilar (adalimumab) development sample,… Read More

#News

#Antibodies #Biosimilars #Kinetics #Screening

Fcγ Receptor and Antigen Kinetic Screening for Rapid Biosimilar Downstream Processing Assessment

Demonstrating similarity of biomolecules such as antibodies throughout upstream and downstream production processes is crucial. A rapid testing method is demonstrated using a Humira biosimilar (adalimumab) development sample, which assesses compatibility with three essential ligands in compliance with regulatory standards. This Application Note covers: How to rapidly assess column elution… Read More

#Resources

#Antibodies #Cancer #Cancer research #Diagnostics #Drug discovery #Fibroblasts #Flow Cytometry #Immunology #Oncology #Tumour biology

Podcast: Flow cytometry for drug discovery research

This is the latest episode of the free DDW narrated podcast, titled “Flow cytometry for drug discovery research” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Flow cytometry technologies and cancer associated fibroblasts and Leveraging… Read More

#News

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

New DDW Highlights podcast: 11 March 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It was antibodies hitting the headlines this week, with the discovery of antibodies with… Read More

#News

#Antibodies #Bispecific Antibodies #FDA #Monoclonal antibodies #Neuroscience #Oncology

This week in drug discovery (4-8 March) 

News round-up for 4-8 March by DDW Digital Content Editor Diana Spencer. It was antibodies hitting the headlines this week, with the discovery of antibodies with potential against a new influenza target, the launch of a Phase I trial to investigate a novel type of bispecific antibody, and… Read More

#News

Antibodies
#Antibodies #Flu #Flu vaccine #Immunology / Virology & Vaccines #Influenza #National Institutes of Health (NIH)

Novel antibodies target ‘dark side’ of influenza virus protein

Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored ‘dark side’ of the neuraminidase (NA) protein head. The antibodies target a region of the NA protein that is common among many… Read More

#Editor's Choice #News

Antibodies
#Antibodies #Oncology #Phase I trial #Solid tumours

Antibody therapy shows anti-tumour activity in advanced cancer

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. Both medications tested in the trial support immune responses against tumour cells. CS1002 increases the activation and proliferation of… Read More

#Cancer Research #News

#Addiction #Antibodies #Cessation Therapeutics #Drug abuse #Monoclonal antibodies #Opioids #Overdose

Can an antibody therapy prevent fentanyl overdoses?

DDW Editor Reece Armstrong speaks to Tracy M Woody, President and Chief Executive Officer of Cessation Therapeutics, about the company’s goal to develop an antibody therapy to prevent fentanyl overdoses. Cessation Therapeutics is a pharmaceutical company that is developing antibody therapies to prevent and reverse overdosing caused by fentanyl. Recently,… Read More

#Exclusive Content

#Antibodies #Antibody discovery workflow #Therapeutic Antibodies #Twist Bioscience

Every day matters

This paid-for advertorial by Twist Bioscience appeared in the Therapeutic Antibodies Guide – DDW Volume 25 – Issue 1, Winter 2023/2024 Improving gene synthesis speed can reduce workflow times, saving you invaluable time, says Twist Bioscience. Time can mean more than money when you’re studying a deadly pathogen. The importance of speed and… Read More

#Exclusive Content

View from the International Space Station
#Antibodies #BioOrbit #Manufacturing #Start-ups #Therapeutic Antibodies

Why Carol Vorderman’s daughter is taking antibodies into space

A UK-based start-up is developing technology to build a pharmaceuticals factory in space that will make antibody treatments more accessible and easier to administer. BioOrbit is aiming to build the first pharmaceuticals factory in microgravity and are currently developing a platform for large-scale crystallisation of protein… Read More

#Editor's Choice #News #Start-up Zone

Monoclonal antibodies
#Antibodies #Bioproduction #Monoclonal antibodies #Tokyo University of Science

Researchers from Japan take a new approach to enhancing antibodies

Researchers from Tokyo University of Science (TUS) have found a simple, low-cost way to optimise the production of monoclonal antibodies (mAbs) and reduce manufacturing costs. Dr Kyohei Higashi, Associate Professor at TUS, along with a team of researchers, conducted a study to explore the effects of… Read More

#News

Human antibodies
#Animal models #Antibodies #HIV #Immunology / Virology & Vaccines #NIAID

Antibodies protect against HIV in animal studies

Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV vaccine for people. The antibodies – a human broadly neutralsing antibody and two antibodies isolated from previously vaccinated monkeys – target… Read More

#News

Antibodies attack Covid-19
#Antibodies #Covid variants #Covid-19 #Covid-19 treatment #ExeVir Bio #Omicron

Antibody cocktail effective against emerging Covid-19 variants

Biotech company ExeVir Bio has revealed new data demonstrating that its antibodies are effective in neutralising currently circulating Covid-19 Omicron variants. The company says that all authorised SARS-CoV-2 therapeutic antibodies that have been used in the clinic show severe to complete loss of virus neutralisation potency… Read More

#News

#AbCheck #Ampersand Biomedicines #Antibodies #Mergers and acquisitions

Ampersand Biomedicines acquires antibody discovery company

Ampersand Biomedicines has announced the acquisition of antibody discovery technology company AbCheck, previously a wholly-owned subsidiary of Affimed. Ampersand Biomedicines launched out of Flagship Pioneering in March 2023. The company hopes the addition of AbCheck’s discovery platform will enable cost-effective and strategic acceleration of its own Address, Navigate, Determine (AND)… Read More

#Business & Investment #News

Antibodies
#Antibodies #Antibody discovery workflow #Antibody drug conjugate (ADC) #CAR-T #Therapeutic Antibodies

Fortis Life Sciences leads the way in custom antibody discovery

This article is sponsored by Fortis Life Sciences. In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools. Fortis Life Sciences offers… Read More

#News

PEGS Europe posters
#Antibodies #Antibody discovery workflow #Biologics #Drug discovery #Events #PEGS Europe 2023 #Protein engineering

Reflecting on PEGS Europe 2023 

DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023. Here, she shares insight from the annual biologics technology meeting.   Scientific tracks and presentations  Antibody-based cancer therapies   The first presentation attended in the antibody-based cancer therapies track, within the antibody drug… Read More

#Exclusive Content